Loading
NASDAQHealthcareBiotechnology
Latest quote
$10.71
+$0.08 · +0.75%
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
Previous close
$10.71
+$0.08 · +0.75%
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
56
Fair Value
Sentiment
64
Bullish
Risk
44
Elevated Risk
Momentum
67
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
Day range
Current $10.71
52-week range
Current $10.71
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 44.64M USD | 47.54M USD | 21.25M USD | 1.54M USD | — |
| Cost of goods sold | 3.76M USD | 3.18M USD | 1.26M USD | 86K USD | — |
| Gross profit | 40.88M USD | 44.35M USD | 19.99M USD | 1.45M USD | — |
| Research and development | 250K USD | 307K USD | 56K USD | 3.53M USD | 4.98M USD |
| Selling, general, and administrative | 46.91M USD | 41.48M USD | 32.71M USD | 20.51M USD | 12.24M USD |
| Operating expenses | 47.22M USD | 41.88M USD | 33.05M USD | 24.19M USD | 17.22M USD |
| Interest income | 787K USD | 1.59M USD | 441K USD | 195K USD | 54K USD |
| Interest expense | 2.08M USD | 4.07M USD | 3.39M USD | 978K USD | 126K USD |
| Depreciation and amortization | 103K USD | 800K USD | 287K USD | 149K USD | 16K USD |
| Operating income | −6.35M USD | 2.48M USD | −13.06M USD | −22.74M USD | −17.22M USD |
| Net income | −9.74M USD | −436K USD | −16.05M USD | −23.71M USD | −17.35M USD |
Company facts updated Oct 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
